It seems that months of merger talks between French pharma Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 a share for Genzyme, with an option included potentially worth $5 to $6 a share.
Continue reading Sanofi-Aventis, Genzyme Are on the Brink of a Merger
Sanofi-Aventis, Genzyme Are on the Brink of a Merger originally appeared on DailyFinance on Mon, 07 Feb 2011 10:40:00.
Filed Under: Company News, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News